• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

everthing

  • Home
  • About
  • Animals
  • Lastes-posts
  • Medicine
  • NBA All-Star Game
  • Pharmacy
  • Software
  • Contact

Abrocitinib is more effective than dupilumab for the treatment of moderate to severe atopic dermatitis

August 3, 2022 by admin

1. The co-primary endpoints at weeks 2 and 4 were significantly higher with abrocitinib than with dupilumab.

2. The overall incidence of adverse events, such as nausea and acne, was more frequent with abrocitinib, but was mostly mild in severity.

Evidence Rating Level: 1 (Excellent)

Study overview: Topical therapy is often considered a first-line option for the treatment of moderate to severe atopic dermatitis. However, when topical therapies are not sufficient, systemic therapies are often recommended. Dupilumab, an anti-interleukin [IL]-4 receptor antibody and abrocitinib, a Janus kinase [JAK] 1 inhibitor, are two systemic therapies that may play a role in the treatment of atopic dermatitis. To date, however, few studies have compared the relative efficacy of these therapies. This randomized controlled trial aimed to compare the safety and efficacy of abrocitinib versus dupilumab for the treatment of moderate to severe dermatitis. The primary outcome was an improvement in severity, defined by an improvement of 4 or more points on the Peak Pruritus Numerical Rating Scale (PP-NRS4) at week 2 and a 90% or greater improvement in the eczema area and severity index (EASI -90) at week 4. According to study results, a higher proportion of patients in the abrocitinib group achieved the primary endpoint compared to dupilumab. Although general adverse reactions were more frequent in the abrocitinib group, most adverse reactions were considered mild in severity. There were no differences in the number of serious adverse events between groups. A major advantage of this study was that it included participants from different countries, including individuals of different races. This contributes to the external validity of the results.

Click to read the study in The Lancet

Relevant literature: Abrocitinib versus placebo or dupilumab for atopic dermatitis

in-depth [randomized-controlled trial]: As of June 11, 2020 and December 16, 2020, 940 patients were screened for eligibility at 151 locations in 15 different countries. Included were patients ≥ 18 years of age with atopic dermatitis for ≥ 6 months and either 1) use of systemic oral therapy within the past 12 months or 2) inadequate response to topical therapy within the past 6 months. A total of 727 patients (362 in the abrocitinib group and 365 in the dupilumab group) were included. Patients received abrocitinib (200 mg daily) or subcutaneous dupilumab (300 mg every 2 weeks) for a total of 26 weeks with matching placebos in both groups. The primary outcome of PP-NRS4 at week 2 (48%, 95% confidence interval [CI] 43.0-53.4 vs. 26%, 95% CI 15.8-29.5, p<0.0001) and EASI-90 at week 4 (29%, 95% CI 23.8-33.2 vs. 15%, 95% CI 10 .9-18.2), p < 0.0001) was significantly greater in the abrocitinib group than in the dupilumab group, respectively. Abrocitinib was associated with more adverse events (268 of 362 patients, 74%) compared to dupilumab (239 of 365, 65%). Notably, mild nausea (19% vs 2%) and acne or folliculitis (13% vs 3%) were more common with abrocitinib than with dupilumab, respectively. Findings from this study suggest that abrocitinib is more effective than dupilumab in adults with moderate to severe atopic dermatitis.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No work may be reproduced without the express written permission of 2 Minute Medicine, Inc. Ask for licenses here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

.

Related

Filed Under: Medicine Tagged With: abrocitinib, atopic dermatitis, chronic illness, dermatology, dupilumab, eczema, moderate to severe atopic dermatitis, rheumatology

Primary Sidebar

Recent Posts

  • Rare breeds of livestock gain popularity in Maine
  • A case of breast imaging of steatocystoma multiplex: a rare condition involving multiple anatomical regions
  • Expert gives tips to keep pets cool during hot summer days in NH
  • Fewer and fewer OB-GYNs are learning how to perform abortions. What happens if there is no one left?
  • Marijuana Can Make You See Your Relationships Wrong

Recent Comments

  1. A WordPress Commenter on Hello world!

Archives

  • August 2022
  • July 2022
  • June 2022

Categories

  • Animals
  • Lastes-posts
  • Medicine
  • NBA All-Star Game
  • Pharmacy
  • Software

Footer

Design

With an emphasis on typography, white space, and mobile-optimized design, your website will look absolutely breathtaking.

Learn more about design.

Pages

  • About
  • Affiliate Disclosure
  • Contact
  • Homepage
  • Landing Page
  • Privacy Policy
  • Sample Page
  • Terms And Conditions

Content

Our team will teach you the art of writing audience-focused content that will help you achieve the success you truly deserve.

Learn more about content.

Strategy

We help creative entrepreneurs build their digital business by focusing on three key elements of a successful online platform.

Learn more about strategy.

Copyright © 2022 · Genesis Sample on Genesis Framework · WordPress · Log in

Go to mobile version